.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Teva
Fuji
Dow
Daiichi Sankyo
US Army
Citi
Chubb
Queensland Health
Colorcon

Generated: July 21, 2017

DrugPatentWatch Database Preview

CASODEX Drug Profile

« Back to Dashboard

Which patents cover Casodex, and what generic Casodex alternatives are available?

Casodex is a drug marketed by Astrazeneca Pharms and is included in one NDA.

The generic ingredient in CASODEX is bicalutamide. There are twenty-nine drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the bicalutamide profile page.

Summary for Tradename: CASODEX

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list77
Clinical Trials: see list43
Patent Applications: see list6,373
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:CASODEX at DailyMed

Pharmacology for Tradename: CASODEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms
CASODEX
bicalutamide
TABLET;ORAL020498-001Oct 4, 1995ABRXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CASODEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca Pharms
CASODEX
bicalutamide
TABLET;ORAL020498-001Oct 4, 19955,712,251► Subscribe
Astrazeneca Pharms
CASODEX
bicalutamide
TABLET;ORAL020498-001Oct 4, 19951,712,251► Subscribe
Astrazeneca Pharms
CASODEX
bicalutamide
TABLET;ORAL020498-001Oct 4, 19954,636,505*PED► Subscribe
Astrazeneca Pharms
CASODEX
bicalutamide
TABLET;ORAL020498-001Oct 4, 19955,389,613► Subscribe
Astrazeneca Pharms
CASODEX
bicalutamide
TABLET;ORAL020498-001Oct 4, 19954,472,382► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
AstraZeneca
Express Scripts
Healthtrust
QuintilesIMS
Fish and Richardson
Dow
Queensland Health
Covington
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot